2011
Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients
McCance-Katz EF, Moody DE, Prathikanti S, Friedland G, Rainey PM. Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. Drug And Alcohol Dependence 2011, 118: 326-334. PMID: 21596492, PMCID: PMC3272858, DOI: 10.1016/j.drugalcdep.2011.04.013.Peer-Reviewed Original ResearchConceptsBuprenorphine plasma concentrationsWithdrawal symptomsOpiate withdrawalPlasma concentrationsBuprenorphine-maintained patientsBuprenorphine-maintained subjectsDays of rifampinOpioid partial agonistBuprenorphine/naloxoneFirst-line treatmentOpiate withdrawal symptomsSignificant adverse eventsActive metabolite concentrationsOpioid-dependent individualsPlasma buprenorphine concentrationsBuprenorphine pharmacokineticsStable dosesAdverse eventsBuprenorphine doseBuprenorphine therapyAntituberculosis medicationPharmacodynamic interactionsRifampin administrationOpioid dependenceLine treatment
2007
Interaction between buprenorphine and atazanavir or atazanavir/ritonavir
McCance-Katz EF, Moody DE, Morse GD, Ma Q, DiFrancesco R, Friedland G, Pade P, Rainey PM. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug And Alcohol Dependence 2007, 91: 269-278. PMID: 17643869, PMCID: PMC3272856, DOI: 10.1016/j.drugalcdep.2007.06.007.Peer-Reviewed Original ResearchConceptsAtazanavir/ritonavirDrug interactionsMini-Mental State ExaminationOpioid partial agonistPharmacokinetics of atazanavirPharmacokinetics of buprenorphineHIV-negative volunteersEffects of buprenorphineConcentrations of buprenorphineAdverse drug interactionsProtease inhibitor atazanavirAntiretroviral administrationBuprenorphine doseHIV diseaseBuprenorphine treatmentHIV medicationsBuprenorphine/Opioid dependencePharmacodynamic effectsRitonavir concentrationsHealthy controlsOpioid addictionBuprenorphineState ExaminationAtazanavir